These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 19303657

  • 1. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
    Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, Levy M, Penman AG.
    J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
    [Abstract] [Full Text] [Related]

  • 2. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK, Wu DB, Chow PY, Lee VW, Li H.
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [Abstract] [Full Text] [Related]

  • 3. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M, Salomon JA, Jiang H, Gui H, Wang H, Wang J, Richardus JH, Xie Q.
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [Abstract] [Full Text] [Related]

  • 4. Cost effectiveness of screening immigrants for hepatitis B.
    Wong WW, Woo G, Jenny Heathcote E, Krahn M.
    Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
    Liaw YF.
    Semin Liver Dis; 2005 Sep; 25 Suppl 1():40-7. PubMed ID: 16103980
    [Abstract] [Full Text] [Related]

  • 8. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
    Veldhuijzen IK, Toy M, Hahné SJ, De Wit GA, Schalm SW, de Man RA, Richardus JH.
    Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Kim BK, Han KH, Ahn SH.
    Oncology; 2011 Feb; 81 Suppl 1():41-9. PubMed ID: 22212935
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P, Yang Y, Wen F, Wheeler J, Fu P, Li Q.
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [Abstract] [Full Text] [Related]

  • 14. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
    Aggarwal R, Ghoshal UC, Naik SR.
    Natl Med J India; 2002 Dec; 15(6):320-7. PubMed ID: 12540064
    [Abstract] [Full Text] [Related]

  • 15. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
    Ringelhan M, O'Connor T, Protzer U, Heikenwalder M.
    J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
    [Abstract] [Full Text] [Related]

  • 16. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S, Hunt DR, Stone MA, McClune A, Tong MJ.
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [Abstract] [Full Text] [Related]

  • 17. Natural history of chronic hepatitis B REVEALed.
    Chen CJ, Yang HI.
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [Abstract] [Full Text] [Related]

  • 18. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM, da Silva AL, Cherchiglia ML, Andrade EI, de Oliveira GL, Acurcio Fde A.
    Value Health; 2011 Apr; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [Abstract] [Full Text] [Related]

  • 19. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
    Chen TM, Chang CC, Huang PT, Wen CF, Lin CC.
    Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk.
    Chang Y, Lairson DR, Chan W, Lu SN, Aoki N.
    J Eval Clin Pract; 2011 Apr; 17(2):261-7. PubMed ID: 20874834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.